Squamous cell carcinomas of the head and neck (HNSCC) are among the most immunosuppressive human tumors. Tumor-induced and therapy-induced immune suppression may be responsible for disease recurrence seen in over 60% of SCCHN patients receiving curative therapies. Our data indicate that adenosine and PGE2 are among the major immunosuppressive factors in HNSCC. Not only the tumor but also regulatory T cells (Treg) produce these factors, and adaptive Treg accumulate in the tumor microenvironment during tumor progression. Their frequency and function increase after chemoradiation (CRT) and remain elevated for months, potentially contributing to tumor recurrence. In this proposal, we test the hypothesis that restoration of anti-tumor immunity in the microenvironment of HNSCC can be achieved in vitro and in vivo by down-regulating Treg and enhancing Teffector cell (Teff) functions using pharmacologic agents which target the adenosine/PGE2 pathway. In three aims, we propose to: (1) conduct a prospective non-therapeutic longitudinal study in HNSCC patients treated with surgery and CRT to ask whether persistent immune suppression and enhanced activity of the adenosine/PGE2 pathway after CRT contribute to the tumor recurrence;(2) study in vitro effects of the pharmacological blockade of the adenosine/PGE2 pathway on Treg-mediated suppression and potentially concomitant restoration of anti-tumor functions of Teff;and (3) show that metabolic silencing of the adenylyl cyclase and stimulation of phosphodiesterase activity in Teff in vivo promotes anti-tumor immune responses to a multi-epitope vaccine, induces tumor rejection and prolongs survival of 4NQO mice with oral carcinoma. These pre-clinical studies are designed to demonstrate that persistent accumulations of Treg in the human tumor microenvironment are associated with tumor progression and that the pharmacological blockade of a common immunosuppressive pathway alone or in combination with conventional cancer therapy silences Treg, restores anti-tumor immunity and inhibits tumor growth. The potential of this new combinatorial therapy for re-establishing effective anti-tumor immunity following CRT in HNSCC is expected to provide the rationale for its translation to the clinic.

Public Health Relevance

The immuno-suppressive microenvironment of human HNSCC is characterized by accumulations of Treg and dysfunction of anti-tumor effector T cells. Chemoradiation (CRT) increases the adaptive Treg frequency and functions. Adenosine/PGE2 produced by these cells might contribute to poor anti-tumor immunity after therapy and to cancer recurrence. A prospective longitudinal clinical study in HNSCC patients receiving SOC therapy will determine whether post-therapy immune suppression, in part mediated by Treg, can be linked to tumor recurrence. Pharmacological silencing of the adenosine/PGE2 pathway in conjunction with conventional therapies is expected to restore anti-tumor effector functions and prevent recurrence. This pre-clinical project will investigate biologic, mechanistic and therapeutic consequences of the blockade in vitro and in a mouse model of oral carcinoma in hope of restoring anti-tumor functions of immune cells and thus prevent recurrence.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Yovandich, Jason L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Yuan, Jianda; Hegde, Priti S; Clynes, Raphael et al. (2016) Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer 4:3
Whiteside, Theresa L; Ferris, Robert L; Szczepanski, Miroslaw et al. (2016) Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. Head Neck 38 Suppl 1:E494-501
Szajnik, Marta; Czystowska-Kuźmicz, Małgorzata; Elishaev, Esther et al. (2016) Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn 16:811-26
Whiteside, Theresa L (2016) Exosomes and tumor-mediated immune suppression. J Clin Invest 126:1216-23
Whiteside, Theresa L; Demaria, Sandra; Rodriguez-Ruiz, Maria E et al. (2016) Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res 22:1845-55
Muller, Laurent; Mitsuhashi, Masato; Simms, Patricia et al. (2016) Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep 6:20254
Whiteside, Theresa L (2015) The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn 15:1293-310
Jie, Hyun-Bae; Schuler, Patrick J; Lee, Steve C et al. (2015) CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res 75:2200-10
Szczepanski, Miroslaw J; Luczak, Michal; Olszewska, Ewa et al. (2015) Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis. J Mol Med (Berl) 93:305-14
Santegoets, Saskia J A M; Dijkgraaf, Eveline M; Battaglia, Alessandra et al. (2015) Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 64:1271-86

Showing the most recent 10 out of 27 publications